{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:39:29Z","timestamp":1788377969672,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12288-024-01944-2","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T20:13:16Z","timestamp":1734725596000},"page":"987-991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparable Short Term Outcomes Among Patients with Newly Diagnosed Acute Myeloid Leukemia with or without Myelodysplasia Related Gene Mutations Treated with Azacytidine-Venetoclax: Observations from a Single Center Retrospective Cohort"],"prefix":"10.1007","volume":"41","author":[{"given":"Rudra Narayan","family":"Swain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarthak","family":"Wadhera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shano","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihant","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"13","key":"1944_CR1","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Mr\u00f3zek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325\u20134336","journal-title":"Blood"},{"issue":"2","key":"1944_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","volume":"18","author":"K Mr\u00f3zek","year":"2004","unstructured":"Mr\u00f3zek K, Heerema NA, Bloomfield CD (2004) Cytogenetics in acute leukemia. Blood Rev 18(2):115\u2013136","journal-title":"Blood Rev"},{"issue":"12","key":"1944_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"9","key":"1944_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125(9):1367\u20131376","journal-title":"Blood"},{"issue":"18","key":"1944_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, D\u00f6hner K, Krauter J, Fr\u00f6hling S, Corbacioglu A, Bullinger L et al (2008) Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med 358(18):1909\u20131918","journal-title":"N Engl J Med"},{"issue":"2","key":"1944_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12288-022-01579-1","volume":"39","author":"R Sharma","year":"2023","unstructured":"Sharma R, Jamwal M, Singh N, Sharma P, Bansal D, Trehan A et al (2023) Genetic spectrum in F13A1 detected by next-generation sequencing among north indian patients with FXIII deficiency. Indian J Hematol Blood Transfus 39(2):276\u2013283","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"1944_CR7","doi-asserted-by":"publisher","first-page":"AB107","DOI":"10.1016\/j.jaci.2010.12.430","volume":"127","author":"K Waterhouse","year":"2011","unstructured":"Waterhouse K, Katta A, Teckman J, Foy T, Derdoy J, Jain A et al (2011) Vitamin D levels in children with eosinophilic esophagitis and gastroesophageal reflux. J Allergy Clin Immunol 127(2):AB107","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"1944_CR8","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"issue":"5","key":"1944_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1182\/bloodadvances.2023011173","volume":"8","author":"O Chan","year":"2024","unstructured":"Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J et al (2024) Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv 8(5):1075\u20131083","journal-title":"Blood Adv"},{"issue":"7","key":"1944_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"D DiNardo Courtney","year":"2020","unstructured":"DiNardo Courtney D, Jonas Brian A, Pullarkat V, Thirman Michael J, Garcia Jacqueline S, Wei Andrew H et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"key":"1944_CR11","doi-asserted-by":"crossref","unstructured":"Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M et al (2024) Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia","DOI":"10.1038\/s41375-024-02230-w"},{"issue":"1","key":"1944_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","volume":"41","author":"E Wang","year":"2023","unstructured":"Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M et al (2023) Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell 41(1):164\u201380e8","journal-title":"Cancer Cell"},{"issue":"6","key":"1944_CR13","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1002\/ajh.26539","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM et al (2022) Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. Am J Hematol 97(6):E214\u2013E6","journal-title":"Am J Hematol"},{"issue":"4","key":"1944_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG et al (2024) Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927\u2013935","journal-title":"Blood Adv"},{"issue":"2","key":"1944_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M et al (2024) Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol 99(2):193\u2013202","journal-title":"Am J Hematol"},{"issue":"21","key":"1944_CR16","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144(21):2169\u20132173","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01944-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-024-01944-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01944-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:07:47Z","timestamp":1760177267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-024-01944-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1944"],"URL":"https:\/\/doi.org\/10.1007\/s12288-024-01944-2","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study has been approved by the institute ethical committed vide letter no.CHMO\/2024\/749.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from participants (or their parent\/legal guardian\/next of kin) to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}